The HLA-C gene sits at the heart of the immune system's antigen presentation machinery, producing the HLA-C protein that displays peptide fragments to CD8+ cytotoxic T cells¹¹ CD8+ cytotoxic T cells
MHC class I molecules present endogenous peptides to CD8+ T cells, enabling immune surveillance of cellular protein content. One particular version of this protein — encoded by the HLA-C*06:02 haplotype — is the strongest single genetic risk factor for psoriasis, accounting for the largest fraction of genetic predisposition²² the largest fraction of genetic predisposition
HLA-C*06:02 on PSORS1 is the primary psoriasis susceptibility allele in Caucasian populations, responsible for a large fraction of familial risk to early-onset disease in European populations. The SNP rs4406273, located approximately 28.7 kb upstream of HLA-C, acts as a near-perfect proxy for the HLA-C*06:02 allele — across European, South Asian, and Southeast Asian cohorts, genotype concordance is 0.984–0.996 (r²=0.946–0.984), making this single SNP almost as informative as full HLA typing.

The Mechanism

HLA-C*06:02 drives psoriasis through a specific autoimmune pathway targeting skin melanocytes. The critical autoantigen is ADAMTS-like protein 5 (ADAMTSL5)³³ ADAMTS-like protein 5 (ADAMTSL5)
ADAMTSL5 is highly expressed in psoriasis lesions, especially in melanocytes; ADAMTSL5-specific CD8+ T cells are detectable in patients and produce IL-17A, a peptide that HLA-C*06:02 presents to skin-infiltrating CD8+ T cells. These T cells produce the pathogenic cytokine IL-17A⁴⁴ IL-17A
IL-17A stimulation of keratinocytes drives the epidermal hyperproliferation that produces psoriatic plaques, which drives keratinocyte hyperproliferation and the characteristic plaques of psoriasis vulgaris. Carriers of HLA-C*06:02 have odds ratios for psoriasis ranging from 3.4 to 4.9 depending on the population studied.

The interaction with ERAP1 (endoplasmic reticulum aminopeptidase 1) reveals an elegant molecular specificity: ERAP1 trims peptide precursors⁵⁵ trims peptide precursors
ERAP1 acts as a gatekeeper, trimming NH2-terminal extended precursors to the exact peptide length required for HLA-C*06:02 binding and presentation to the optimal size for HLA-C*06:02 binding. Different ERAP1 haplotypes produce different amounts of the ADAMTSL5 autoantigen, meaning ERAP1 variants only influence psoriasis risk in HLA-C*06:02 carriers⁶⁶ ERAP1 variants only influence psoriasis risk in HLA-C*06:02 carriers
ERAP1 variants confer risk only in individuals with the HLA-C risk allele; no effect in non-carriers, establishing HLA-C as a prerequisite for ERAP1-mediated risk — an example of genetic epistasis where the effect of one gene depends entirely on the context of another.

The Evidence

The landmark psoriasis GWAS by Strange et al. 2010⁷⁷ The landmark psoriasis GWAS by Strange et al. 2010
Large multi-cohort GWAS identifying new psoriasis loci including the HLA-C × ERAP1 epistatic interaction, P_combined=6.95×10−6 established the HLA-C/ERAP1 interaction and confirmed HLA-C as the primary PSORS1 signal. Stuart et al. 2015 validated rs4406273⁸⁸ Stuart et al. 2015 validated rs4406273
Genotype concordance 0.984–0.996; sensitivity 0.965–1.000; specificity 0.9963–0.9994 as a surrogate for HLA-C*06:02 across European, Asian, and some African and admixed populations as an excellent single-SNP surrogate across multiple diverse cohorts, reporting ORs of 3.38, 2.32, and 4.91 in Michigan, Pakistani, and Thai samples respectively.

HLA-C*06:02 status has emerged as a clinically useful predictive biomarker⁹⁹ clinically useful predictive biomarker
Meta-analysis (937 patients at 6-month timepoint); risk difference of 0.24 (95% CI 0.14–0.35, P<0.001) in PASI75 response favoring HLA-C*06:02-positive patients on ustekinumab for biologic drug response in psoriasis. HLA-C*06:02-positive patients achieve substantially higher response rates on ustekinumab (anti-IL-12/IL-23) — approximately 89–92% achieving PASI75 at 6 months versus 62–67% in HLA-C*06:02-negative patients.

Phenotypically, HLA-C*06:02-positive patients are more likely to present with guttate lesions, greater body surface area, and higher PASI scores¹⁰¹⁰ guttate lesions, greater body surface area, and higher PASI scores
HLA-Cw6 positivity associated with guttate psoriasis, greater body surface area, and higher PASI scores in multiple cohorts and earlier disease onset (type I psoriasis, onset before age 40).

Practical Actions

HLA-C*06:02 carrier status (tagged by rs4406273-A) has direct, genotype-specific clinical implications. If you carry one or two copies of the A allele, your dermatologist should be informed: this genotype predicts better response to ustekinumab (Stelara) and poorer relative benefit from some other biologics. It also warrants heightened awareness of early psoriasis symptoms — particularly following streptococcal throat infections, which are a known trigger for guttate flares specifically in HLA-C*06:02 carriers.

Homozygous AA carriers face substantially elevated risk and should establish regular dermatological follow-up even without current disease, since psoriasis is often preceded by subclinical immune activation. Triggers known to unmask or exacerbate psoriasis in HLA-C*06:02 carriers include streptococcal infections, stress, skin trauma (Koebner phenomenon), and certain medications (lithium, beta-blockers).

Interactions

The most important interaction is with ERAP1 (rs27524). ERAP1 risk alleles only increase psoriasis susceptibility in individuals who also carry the HLA-C risk allele. A user carrying risk alleles at both rs4406273 (HLA-C*06:02 proxy) and rs27524 (ERAP1) has a substantially higher combined risk than either variant alone, because ERAP1 controls the generation of the very autoantigen that HLA-C*06:02 presents to pathogenic T cells.

The related SNP rs12191877 is another HLA-C*06:02 tagging SNP at a different position; both co-segregate with the same HLA-Cw6 haplotype and share near-identical psoriasis associations. They provide complementary coverage for HLA-C*06:02 detection rather than marking independent biological signals.

The melanocortin-4 receptor (MC4R) sits at the centre of the hypothalamus's appetite control system. When the brain releases satiety signals — leptin-driven alpha-melanocyte stimulating hormone¹¹ alpha-melanocyte stimulating hormone
α-MSH, derived from the POMC precursor peptide in hypothalamic neurons — MC4R receives them, suppressing hunger and raising energy expenditure. Rare coding mutations in MC4R cause severe monogenic obesity; common variants near the gene produce subtler, population-wide effects on body weight. rs489693 belongs to this second category: an intergenic variant located approximately 155 kilobases downstream of MC4R on chromosome 18, within a regulatory region that influences MC4R locus activity.

What makes rs489693 distinctive within the MC4R neighbourhood is its clinical specificity. Unlike rs17782313 (the strongest common MC4R-region obesity signal), rs489693 was discovered through a pharmacogenomics GWAS²² pharmacogenomics GWAS
genome-wide association study restricted to patients being treated with antipsychotic medications rather than a general population obesity scan. The A allele acts recessively — heterozygous AC carriers show modest effects, while AA homozygotes (about 10% of Europeans) experience markedly amplified weight gain when prescribed second-generation antipsychotics.

The Mechanism

rs489693 has no protein-coding consequence — it lies in intergenic DNA without a documented transcript. Its functional effect is presumed to be regulatory: the variant likely resides in an enhancer or repressor element³³ enhancer or repressor element
non-coding DNA that controls when and how much a nearby gene is expressed that modulates MC4R expression in hypothalamic or limbic tissue. Second-generation antipsychotics (SGAs) such as olanzapine and clozapine are known to antagonise histamine H1 and serotonin 5-HT2C receptors, triggering increased appetite and reducing energy expenditure. Reduced MC4R-mediated satiety tone appears to compound this drug effect: when the melanocortin brake on appetite is already weakened by genetic variation at this locus, the appetite-stimulating actions of SGAs go less opposed, producing larger weight increases.

The Malhotra et al. 2012 GWAS⁴⁴ Malhotra et al. 2012 GWAS
139 pediatric patients in discovery, three independent replication cohorts, total n=344 found that AA homozygotes showed not only greater weight gain but also consistent elevations in triglycerides, leptin, and insulin — a full metabolic syndrome profile. This suggests the variant influences an MC4R-mediated pathway that governs both appetite and peripheral metabolic signalling.

The Evidence

The pharmacogenomics signal at rs489693 is among the most robustly replicated in antipsychotic-induced weight gain (AIWG) research. The pivotal study by Malhotra et al.⁵⁵ Malhotra et al.
GWAS with three independent replication cohorts across US and European psychiatric centres achieved genome-wide significance (p=5.59×10^-12) in meta-analysis across cohorts — one of the few pharmacogenomics variants to reach this threshold for any drug-induced side effect.

A subsequent naturalistic study by Czerwensky et al. 2013⁶⁶ Czerwensky et al. 2013
341 Caucasian inpatients on SGAs including olanzapine, clozapine, risperidone, paliperidone, quetiapine, and amisulpride found that AA homozygotes gained 2.2 times as much weight as CC carriers after four weeks of treatment (+2.2 kg vs +1.0 kg, p=0.039). In the subgroup without weight-gain-inducing co-medications, the difference was 3.1-fold; in first-episode patients, 2.7-fold — both p<0.05. This confirms the signal is not confounded by prior drug exposure and is strongest when the genetic variant can be evaluated in isolation.

A 2026 meta-analysis⁷⁷ 2026 meta-analysis
75 studies examined in systematic review, all adult patients with severe mental illness prescribed antipsychotics confirmed rs489693 as one of six pharmacogenomics loci reaching significance across the AIWG literature (Hedge's g=0.127). Notably, five of the six replicated genes regulate hypothalamic appetite and satiety pathways — MC4R, HTR2C, LEPR, ADRA2A, and CNR1 — pointing to a convergent mechanism through central appetite regulation rather than peripheral metabolic effects.

A real-world polygenic risk score⁸⁸ real-world polygenic risk score
incorporating rs489693 plus five other AIWG variants in first-episode psychosis patients predicted weight gain with adjusted r²=0.59 in females, though the PRS showed no significant effect in males — a sex-specific finding that requires replication but highlights the importance of considering sex as a biological variable in AIWG prediction.

Practical Actions

For AA homozygotes, the most clinically useful application is pre-treatment risk stratification. Before starting a high-weight-gain-liability SGA (olanzapine, clozapine, quetiapine, or risperidone), knowing you carry the AA genotype provides a genetic rationale for discussing lower-weight-gain alternatives with your prescriber — aripiprazole, lurasidone, and ziprasidone have substantially lower AIWG profiles in the general population, and genetic risk strengthens the case for preferring them when clinically equivalent.

When SGA treatment is medically necessary and cannot be changed, proactive metabolic monitoring becomes essential. AA carriers should have baseline and regular follow-up measures of weight, waist circumference, fasting glucose, triglycerides, and HbA1c — the full metabolic syndrome panel. Early detection of metabolic drift enables earlier intervention (lifestyle, metformin adjunct, or medication review) before frank metabolic syndrome develops.

Timing matters: the Czerwensky 2013 data shows 2.2 kg excess gain in just four weeks, before many patients would be flagged by routine clinical review. More frequent early weight monitoring (weekly for the first month) in AA carriers could prompt earlier clinical response.

Interactions

rs17782313 (MC4R near-gene variant): Both variants tag the MC4R locus, but they are not in strong linkage disequilibrium and appear to capture partially independent signals. rs17782313 is primarily an obesity signal in the general population; rs489693 is primarily an antipsychotic-weight-gain signal. Carriers of risk alleles at both loci may have compound MC4R-pathway vulnerability — both general appetite dysregulation and amplified drug-induced weight gain. The combined effect has not been quantified in a single study.

rs8087522 (MC4R upstream regulatory variant): A second MC4R upstream variant ~155 kb from the TSS with an exploratory association with clozapine-induced weight gain in European-ancestry patients (PMID 22310352). The rs489693 and rs8087522 signals may partially overlap or independently contribute to MC4R regulatory tone. Combined effects have not been formally assessed.

HTR2C rs3813929: The serotonin 2C receptor variant is the strongest single-gene AIWG signal (Hedge's g=0.76 in the Warner-Levy 2026 meta-analysis). Antipsychotics cause weight gain partly through 5-HT2C antagonism; MC4R pathway impairment at rs489693 operates through a different mechanism (reduced satiety tone). Carriers of risk alleles at both loci face additive AIWG risk through independent pathways, making a combined pharmacogenomics assessment more predictive than either alone.

Non-obstructive azoospermia (NOA) is the complete absence of sperm in semen due to a failure of sperm production in the testes — the most severe form of male infertility, affecting roughly 1% of all men and approximately 10% of infertile men. Unlike obstructive azoospermia (where a physical blockage prevents sperm from reaching the ejaculate), NOA reflects a fundamental spermatogenic failure¹¹ spermatogenic failure
inability of the testes to produce mature sperm through the meiotic and mitotic divisions of spermatogenesis. Genetic factors account for a substantial proportion of NOA cases. Chromosome abnormalities (e.g. Klinefelter syndrome, Y microdeletions) are the most common causes, but common variants of modest effect — particularly in the HLA region — have also been implicated.

The Mechanism

rs498422 lies in an intronic region of LOC101929163 (also annotated as TSBP1-AS1), a non-coding antisense RNA gene situated on chromosome 6p21.32 between TSBP1 (testis-expressed basic protein 1) and BTNL2 (butyrophilin-like protein 2). This locus sits within the extended major histocompatibility complex (MHC)²² major histocompatibility complex (MHC)
the HLA region, spanning ~4 Mb on chromosome 6p21, encoding immune-recognition proteins and dozens of regulatory genes. The precise causal mechanism is not established. The intronic position suggests the G allele may tag a haplotype that influences the expression of nearby genes, particularly TSBP1 (expressed in testis) or BTNL2 (a co-stimulatory molecule involved in immune regulation). Given the strong immune-regulatory role of the HLA region, one leading hypothesis is that certain MHC haplotypes alter testicular immune tolerance — creating a milieu in which the immune system fails to appropriately protect germ cells from autoimmune attack.

The Evidence

The primary evidence comes from a landmark genome-wide association study by Zhao et al. 2012³³ genome-wide association study by Zhao et al. 2012
A genome-wide association study reveals that variants within the HLA region are associated with risk for nonobstructive azoospermia. Am J Hum Genet, 2012, conducted in Han Chinese men across three independent stages: discovery (802 NOA cases, 1,863 controls), northern China replication (818 cases, 1,755 controls), and central/southern China replication (606 cases, 958 controls), totalling 2,226 cases and 4,576 controls. rs498422 at the C6orf10/BTNL2 region reached a combined p-value of 2.43 × 10⁻¹², with an odds ratio of 1.42 — a statistically robust finding that survived genome-wide significance thresholds after multiple-testing correction.

A subsequent case-control study and meta-analysis by Zou et al. 2017⁴⁴ case-control study and meta-analysis by Zou et al. 2017
Association and meta-analysis of HLA and non-obstructive azoospermia in the Han Chinese population. Andrologia, 2017 in 603 NOA cases and 610 controls replicated the association (OR 1.40, p = 0.006). A meta-analysis across five studies confirmed that the three HLA-region loci including rs498422 are consistently associated with NOA susceptibility (p < 0.01 across all), leading the authors to propose these variants as potential diagnostic markers for male infertility risk.

A replication study in Japanese men by Jinam et al. 2013⁵⁵ replication study in Japanese men by Jinam et al. 2013
HLA-DPB1*04:01 allele is associated with non-obstructive azoospermia in Japanese patients. Hum Genet, 2013 (443 patients, 544 controls) showed that the correlated marker rs3129878 (in linkage disequilibrium with rs498422) was associated with NOA in a Japanese population, though HLA-DPB1*04:01 emerged as the primary independently associated allele in that cohort. This confirms the broader HLA-region involvement in NOA across East Asian populations.

Critical limitation: All replication data are from East Asian populations (Han Chinese and Japanese). The G allele of rs498422 is approximately three times more common in East Asians (~18%) than in Europeans (~6%), and the MHC haplotype structure differs substantially between populations. No replication data exist for European, African, South Asian, or Latino men. Until independent replication in non-East-Asian populations is published, this association should be considered population-specific and the evidence classified as emerging for general population use.

Practical Actions

For men of East Asian ancestry, carrying G alleles at rs498422 modestly elevates the prior probability of spermatogenic impairment. The OR of 1.42 means that, in the context of an infertility evaluation, this genotype adds modest incremental information — it does not diagnose NOA or predict it with high certainty, but it can inform how aggressively to investigate spermatogenesis, particularly in the context of other risk factors such as a history of orchitis, cryptorchidism, or prior chemotherapy.

Semen analysis remains the essential diagnostic test. Men with G alleles who are pursuing fertility and have not had a semen analysis should consider obtaining one. If NOA is diagnosed, the presence of this risk genotype does not change management — NOA is evaluated with hormonal testing, testicular biopsy, and potential surgical sperm retrieval regardless of genotype.

Interactions

rs498422 is in linkage disequilibrium with rs3129878 (HLA-DRA) and rs7194, two other HLA-region variants associated with NOA. In the Zhao et al. 2012 GWAS, rs498422 and rs3129878 showed independent signals after conditioning on each other, suggesting they may tag distinct functional effects within the MHC. A 2019 fine-mapping study (Huang et al., PMID 30502936) identified additional loci (rs7194, rs4997052) within the MHC class I region, suggesting that multiple independent signals in the HLA region collectively contribute to NOA susceptibility — possibly through different immune mechanisms acting on spermatogenesis. Men who carry risk alleles at multiple HLA-region NOA loci may have cumulatively higher risk, though formal compound analysis of this specific combination has not been published.

In the collecting tubule of the kidney, a molecular handshake determines how much salt your body holds onto each day. The epithelial sodium channel (ENaC) sits at the apical membrane of tubular cells and controls the final step of sodium reabsorption. How long ENaC stays at the cell surface — and therefore how much sodium it captures — depends critically on the NEDD4L protein, an E3 ubiquitin ligase that marks ENaC subunits for removal and degradation. Genetic variants in NEDD4L that alter this regulatory efficiency create a spectrum of salt handling phenotypes, with direct consequences for blood pressure and cardiovascular risk. The intronic rs549476 variant lies within this regulatory locus and tags haplotypes associated with altered NEDD4L isoform expression and hypertension susceptibility.

The Mechanism

NEDD4L encodes an HECT-domain E3 ubiquitin ligase¹¹ E3 ubiquitin ligase
An enzyme that attaches ubiquitin tags to target proteins, marking them for proteasomal or lysosomal degradation that specifically targets the β- and γ-subunits of ENaC through their C-terminal PY (proline-tyrosine) motifs. After binding, NEDD4L catalyzes the transfer of ubiquitin chains to ENaC, triggering internalization and degradation of the channel from the cell surface. Less ENaC at the membrane means less sodium reabsorption and, ultimately, lower extracellular fluid volume and blood pressure.

The rs549476 variant is intronic and tags a haplotype that affects NEDD4L isoform balance. The closely linked functional variant rs4149601, at the last nucleotide of exon 1, creates a cryptic splice site²² cryptic splice site
A splice site normally suppressed; when activated by a variant, it causes alternative splicing. The G allele at rs4149601 generates isoform I, which retains the Ca²⁺-dependent lipid-binding C2 domain; this C2-domain-containing isoform interacts less efficiently with ENaC under high-sodium conditions. Carriers of the G haplotype therefore reabsorb more sodium under salt challenge, producing higher blood pressure and greater salt sensitivity³³ salt sensitivity
A blood pressure increase of ≥10 mmHg in response to a sodium load.

The renin-angiotensin-aldosterone system (RAAS) responds by suppressing renin — GG carriers show significantly lower plasma renin concentrations under salt loading, confirming that their kidneys are already retaining excess sodium relative to the system setpoint.

The Evidence

The clinical evidence for NEDD4L variants and salt-sensitive hypertension comes from several independent cohorts. In a Swedish crossover study of 39 normotensive subjects, individuals carrying the high-risk NEDD4L haplotype (GG at rs4149601 plus CC at rs2288774) showed salt sensitivity of 8.0 mmHg versus 5.0 mmHg in non-carriers (P=0.007)⁴⁴ individuals carrying the high-risk NEDD4L haplotype (GG at rs4149601 plus CC at rs2288774) showed salt sensitivity of 8.0 mmHg versus 5.0 mmHg in non-carriers (P=0.007)
Holmberg et al. Polymorphism in NEDD4L is associated with increased salt sensitivity. PLoS One, 2007, with accompanying suppression of plasma renin (9.0 vs 15.0 mU/L, P=0.03) and elevation of N-terminal pro-atrial natriuretic peptide.

The population-scale impact was established in the Malmö Diet and Cancer Study of 27,564 participants⁵⁵ Malmö Diet and Cancer Study of 27,564 participants
Dahlberg et al. Genetic variation in NEDD4L is associated with cardiovascular disease and cardiovascular death. J Hypertens, 2014: carriers of the NEDD4L salt-sensitivity genotype had higher systolic BP (142 vs 141 mmHg, P=0.002) and diastolic BP (86.0 vs 85.6 mmHg, P=0.025), with a multivariate hazard ratio of 1.13 for cardiovascular disease (P=0.018) and 1.20 for coronary events (P=0.005) over 14 years of follow-up.

The pharmacogenomics implications are clinically important. In the PEAR trial of 767 hypertensive patients⁶⁶ PEAR trial of 767 hypertensive patients
Bress et al. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens, 2013, NEDD4L G-allele carriers on hydrochlorothiazide achieved significantly greater blood pressure reductions than non-carriers, consistent with the salt-retaining phenotype being particularly responsive to diuretic therapy.

Practical Actions

The actionable takeaway from the NEDD4L literature is clear: individuals with the salt-retaining genotype benefit disproportionately from sodium restriction and from diuretic antihypertensive therapy. Reducing dietary sodium from a typical 3,400 mg/day to below 1,500 mg/day can lower systolic blood pressure by 5–8 mmHg in salt-sensitive individuals — a reduction comparable to some antihypertensive medications. For those who require pharmacological treatment, thiazide diuretics are particularly effective in this genetic context, and this information should inform antihypertensive prescribing decisions.

Interactions

rs549476 tags a haplotype in LD with the functionally characterized rs4149601 and rs2288774 variants. The combined GG+CC haplotype at these two positions confers the highest salt-sensitivity phenotype, present in approximately 9.6% of European populations.

The NEDD4L pathway also interacts with the alpha-adducin (ADD1 rs4961) and WNK1 variants in a convergent renal sodium-handling network. In a physiological interaction study⁷⁷ In a physiological interaction study
Manunta et al. Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways. Hypertension, 2008, the combination of ADD1 Trp allele plus WNK1 GG plus NEDD4L GA/AA showed consistent synergistic effects on nocturnal blood pressure, thiazide response, and acute saline-challenge BP. Users carrying risk variants in both pathways should be particularly attentive to sodium intake.

Von Willebrand factor is not a single molecule but a polymer — its biological power comes from assembling into enormous high-molecular-weight multimers¹¹ high-molecular-weight multimers
Ultra-large VWF strings secreted by endothelial cells after injury; these structures are the only form capable of capturing platelets under high arterial shear conditions; loss of these multimers is the defining feature of type 2A von Willebrand disease that can deploy across a damaged vessel wall and capture flowing platelets within microseconds. The A2 domain of VWF contains the cleavage site for ADAMTS13²² ADAMTS13
A disintegrin and metalloproteinase with thrombospondin motifs 13; a circulating metalloprotease that trims VWF multimers to normal size under shear; overactivity or hypersusceptibility causes loss of the largest, most hemostatically active multimers — a protease that regulates multimer size by cutting the chain. The A2 domain is normally kept tightly folded, burying the ADAMTS13 cleavage site and protecting the multimer from premature destruction. The rs61750581 S1613P substitution — a serine-to-proline change at position 1613 — replaces a flexible amino acid with proline, which kinks the local backbone and destabilizes the A2 domain fold. The result is a VWF multimer that is proteolyzed too readily, depleting the high-molecular-weight forms needed for normal hemostasis.

This variant is listed as OMIM allelic variant 613160.0009 for von Willebrand disease type 2A. As of February 2025, the ClinGen von Willebrand Disease Variant Curation Expert Panel reclassified it from pathogenic to Uncertain Significance (VUS), based on emerging criteria for VWD-specific variant interpretation. It meets PP3 (computational evidence of pathogenicity), PS4_Supporting (case enrichment), and PP4_Moderate (phenotype specificity), but does not yet have sufficient independent evidence to satisfy full pathogenicity criteria under current VWD curation rules.

The Mechanism

The VWF A2 domain normally adopts a β-propeller-like fold³³ β-propeller-like fold
A compact secondary structure with hydrophobic core that buries the ADAMTS13 binding region and scissile bond; disruption of this fold is the shared mechanism of all classical type 2A VWD group II mutations that shields the ADAMTS13 cleavage site Tyr1605–Met1606 from protease access. Under arterial shear, unfolding is regulated and transient — but type 2A A2 domain mutations constitutively destabilize this fold even at rest.

A FRET-based assay separating the N- and C-termini of the A2 domain demonstrated that 7 of 8 type 2A mutations tested caused persistent separation of the domain's termini⁴⁴ 7 of 8 type 2A mutations tested caused persistent separation of the domain's termini
Lynch et al., PLoS One 2017 — mutations that separate N- and C-termini promote an open conformation that exposes ADAMTS13 binding and scissile bond sites constitutively, producing a constitutively open conformation that exposes the ADAMTS13 binding and scissile sites. Earlier work confirmed that 11 of 13 A2 domain VWD type 2A mutations increased specific ADAMTS13 proteolysis⁵⁵ 11 of 13 A2 domain VWD type 2A mutations increased specific ADAMTS13 proteolysis
Hassenpflug et al., Blood 2006 — ADAMTS13 susceptibility correlated directly with in vivo multimer loss seen in patient plasma, and that the degree of proteolytic susceptibility correlated directly with the degree of HMWM loss observed in patient plasma.

An in vivo rat model demonstrated that VWF carrying the S1613P mutation undergoes accelerated proteolysis in vivo resulting in loss of high-molecular-weight multimers⁶⁶ accelerated proteolysis in vivo resulting in loss of high-molecular-weight multimers
Stoddart et al., Blood 1996 — the only published experimental evidence specifically characterizing S1613P in a living model; shows the mutation recapitulates the type 2A phenotype with appearance of satellite proteolytic fragments, while overall VWF clearance rates remain comparable to normal protein, meaning the functional deficit is selective: only the large, hemostatically active multimers are lost.

The Evidence

The variant was originally documented as a pathogenic VWD type 2A cause in OMIM based on early molecular characterization and family studies. A recent Thai multicenter study⁷⁷ Thai multicenter study
Lauhasurayotin et al., J Clin Pathol 2024 — 15 patients with type 2 or type 3 VWD genotyped by whole exome sequencing; p.Ser1613Pro identified among previously described mutations using whole exome sequencing identified p.Ser1613Pro among known pathogenic VWF mutations in VWD patients, confirming its presence in affected individuals across populations.

The February 2025 ClinGen reclassification to VUS reflects the evolution of variant interpretation criteria for VWD, not evidence of benignity. The variant has no functional counterevidence — all experimental data support pathogenicity — but specific evidence thresholds under the formal VWD curation rules are not yet fully met. Clinicians encountering this variant in the context of a confirmed bleeding phenotype should treat it as a strong candidate for clinical significance pending future reclassification.

Type 2A VWD — the disease associated with this variant — manifests as mucocutaneous bleeding including epistaxis, easy bruising, heavy menstrual bleeding, and post-surgical hemorrhage⁸⁸ mucocutaneous bleeding including epistaxis, easy bruising, heavy menstrual bleeding, and post-surgical hemorrhage
Seidizadeh et al., Semin Thromb Hemost 2026 — comprehensive clinical update on type 2A VWD. Laboratory hallmarks include a reduced VWF:RCo/VWF:Ag ratio (platelet-binding activity disproportionately lower than antigen level), reduced VWF:CB/VWF:Ag ratio, and selective loss of high- and intermediate-molecular-weight multimers on gel electrophoresis.

Practical Implications

Anyone carrying a G allele at rs61750581 with a personal or family history of unusual bleeding should pursue hematology evaluation. Diagnostic workup should include VWF antigen, VWF ristocetin cofactor activity, VWF collagen binding, FVIII:C, and VWF multimer analysis — the full type 2A laboratory panel. A DDAVP (desmopressin) responsiveness test is appropriate before any procedure, as type 2A heterozygotes can show a transient but often insufficient response⁹⁹ type 2A heterozygotes can show a transient but often insufficient response
Michiels & van Vliet, Acta Haematol 2009 — complete response in mild type 2A lasts only hours; inadequate for surgical prophylaxis in most patients. VWF concentrates containing both VWF and FVIII (Humate-P, Wilate, Vonvendi) are the standard treatment for major bleeding events and surgical prophylaxis.

Women with this variant are at particular risk for heavy menstrual bleeding, which often precedes formal VWD diagnosis by years and significantly impacts quality of life. Menorrhagia in VWD carriers is managed with tranexamic acid, hormonal therapies, or VWF concentrates for severe episodes.

Interactions

VWF S1613P interacts with the general VWF expression level: individuals with an additional low-VWF variant in the other allele may have more pronounced bleeding phenotypes than those with a single functional copy of normal VWF. Blood group O is a well-established environmental modifier — O type individuals have 25–35% lower plasma VWF levels than non-O individuals, which can worsen bleeding phenotype in anyone with a heterozygous VWF functional variant. Blood group O status should be noted when evaluating type 2A carriers clinically.

PXK¹¹ PXK
PX domain containing serine/threonine kinase like; a protein containing a phox homology (PX) domain that binds phosphoinositide lipids on endosomal membranes, positioning it in the trafficking machinery that sorts internalized receptors for recycling or degradation is a gene most people have never heard of — yet a variant within its intron has appeared consistently in genome-wide association scans for systemic lupus erythematosus (SLE) in European populations. The rs6445975 G allele was one of four loci with genome-wide significant replication in the landmark 2008 SLEGEN consortium study, placing PXK alongside more familiar SLE genes like ITGAM and STAT4. What makes PXK biologically interesting is its proposed role in controlling how immune cells terminate signalling after receptor engagement — a cellular housekeeping function with outsized consequences when disrupted in autoimmune contexts.

The Mechanism

PXK's PX domain binds phosphatidylinositol 3-phosphate (PtdIns3P)²² phosphatidylinositol 3-phosphate (PtdIns3P)
A phospholipid lipid enriched on the cytoplasmic face of early endosomes; serves as a docking signal for proteins involved in vesicle trafficking, autophagy, and receptor sorting, the signature lipid of early endosomes. This positions PXK in the endosomal sorting machinery — the cellular system that decides, after a surface receptor is internalized, whether it is recycled back to the cell surface or directed to the lysosome for degradation. Epidermal growth factor receptor (EGFR) was identified as one cargo whose degradation is regulated by proteins in the PtdIns3P-binding family that includes PXK, based on siRNA screening data.

The immune relevance is that B-cell receptor (BCR) internalization follows a mechanistically similar endosomal sorting pathway. When the BCR binds antigen, it is rapidly internalized and trafficked through endosomes for antigen processing and presentation. The efficiency of this internalization — and therefore the strength and duration of the resulting immune activation — is regulated by the same PtdIns3P-dependent endosomal machinery in which PXK participates. Reduced or altered PXK function could impair the timely termination of BCR signalling, allowing prolonged immune activation. In lupus, where B cells are already hyperactivated and produce pathogenic autoantibodies, any genetic variant that prolongs BCR signalling is a plausible contributor to disease susceptibility.

rs6445975 sits in an intron of PXK, suggesting it acts as a regulatory variant — altering expression levels or splicing of PXK isoforms in specific immune cell types rather than changing the protein sequence directly. The exact functional consequence at the molecular level has not been characterised in published eQTL studies, making the mechanistic link to BCR trafficking inferential rather than directly demonstrated.

The Evidence

The variant was first identified in the landmark 2008 SLEGEN genome-wide scan³³ landmark 2008 SLEGEN genome-wide scan led by Harley and colleagues, which examined 720 women with SLE plus 2,337 controls in the discovery cohort, with replication in a further 1,846 cases and 1,825 controls. PXK (along with ITGAM, KIAA1542, and other loci) showed evidence of association with replication across the study cohorts.

The most precise quantification comes from a 2012 meta-analysis by Lee et al.⁴⁴ 2012 meta-analysis by Lee et al. synthesising 13 studies: the rs6445975 G allele was associated with SLE at OR 1.151 (95% CI 1.086–1.291, p=1.8×10⁻⁶) in the overall population, with a stronger signal in European subgroups (OR 1.198, 95% CI 1.118–1.285, p=3.4×10⁻⁷). Notably, the Asian subgroup showed no significant association — a finding replicated independently⁵⁵ replicated independently in 910 Hong Kong Chinese SLE patients (OR 1.06, p=0.36) and Korean patients⁶⁶ Korean patients (OR 1.06, p=0.57). This population specificity is consistent with different linkage disequilibrium⁷⁷ linkage disequilibrium
The non-random association of alleles at two or more loci; a tagging SNP may associate strongly with a causal variant in one population but not another if LD patterns differ across ancestries (LD) structure around the locus across ancestries.

The strongest per-genotype effect sizes come from a 2022 Iranian case-control study⁸⁸ 2022 Iranian case-control study (110 SLE patients, 115 controls): GG homozygotes showed an OR of 7.5 versus TT (95% CI 3.47–17.07), and G allele carriers overall had a 3.55-fold elevated risk. The G allele also correlated with elevated inflammatory markers (CRP, ESR), anti-dsDNA antibody levels, complement consumption (C3/C4 abnormalities), renal involvement, and skin lesions. A Chinese cohort study⁹⁹ Chinese cohort study reinforced the autoantibody connection even in a population where overall SLE risk was not significantly elevated: the G allele was significantly associated with anti-Smith (OR 1.95), anti-Ro (OR 1.69), and anti-La (OR 1.86) antibodies — suggesting that PXK influences the specificity and breadth of autoantibody production independently of overall disease susceptibility.

The evidence level is moderate: the association is consistently replicated in European populations across multiple independent cohorts and a meta-analysis, the OR per allele (~1.15–1.2) is modest but statistically robust, and the biological mechanism (endosomal receptor trafficking) is plausible. However, the causal variant has not been identified, eQTL studies have not definitively linked rs6445975 to PXK expression, and the Asian non-replication raises questions about whether rs6445975 is the causal variant or a tagging SNP in partial LD with the functional locus.

Practical Implications

For G allele carriers — particularly those of European ancestry — the practical implications focus on early detection and proactive monitoring for early lupus features, rather than on any specific nutrient or supplement intervention. SLE is an episodic, multi-system disease whose early signs (photosensitivity, butterfly rash, joint pain, unexplained fatigue, serositis) are often attributed to other causes for years before diagnosis. The OR of ~1.15–1.2 per G allele is modest in isolation, but GG homozygotes appear to carry a substantially higher burden in Middle Eastern cohorts. Any G allele carrier with a first-degree relative with lupus, or with recurrent unexplained symptoms across multiple organ systems, has grounds to request early ANA (antinuclear antibody) screening.

Hydroxychloroquine is the cornerstone treatment for SLE and has been shown to reduce disease flares, prevent organ damage, and improve survival. Carriers of elevated-risk genotypes who are diagnosed with SLE or an undifferentiated connective tissue disease should be aware that early initiation of hydroxychloroquine is recommended by ACR/EULAR guidelines.

Interactions

The PXK locus exists within a broader landscape of SLE genetic susceptibility. STAT4 (rs7574865)¹⁰¹⁰ STAT4 (rs7574865) is one of the most strongly replicated SLE risk loci (OR ~1.5–1.7), acting through interferon-γ signalling in T cells. PTPN22 (rs2476601)¹¹¹¹ PTPN22 (rs2476601) is a well-established autoimmune risk variant disrupting T-cell and B-cell receptor signalling thresholds, also in the GeneOps database. BLK (rs13277113)¹²¹² BLK (rs13277113) encodes a B-lymphocyte kinase directly involved in BCR signalling — the same pathway that PXK's endosomal role putatively modulates. Carrying multiple SLE risk alleles across STAT4, BLK, PTPN22, and PXK represents an additive polygenic risk burden significantly exceeding any single locus. No specific compound action has been formally documented for PXK + BLK, but the biological logic of convergent BCR-pathway disruption is strong.

Your kidneys filter roughly 70% of the uric acid your body excretes each day, and the SLC2A9 gene — encoding the GLUT9 transporter¹¹ GLUT9 transporter
Glucose Transporter 9, a voltage-sensitive high-capacity urate transporter expressed on the basolateral membrane of the renal proximal tubule — is the single most important genetic regulator of how efficiently that process happens. rs6852441 is an intronic variant that tags a regulatory haplotype within this gene, with a population frequency pattern that mirrors the established risk architecture of the SLC2A9 locus: high risk-allele frequency in East Asians (where gout prevalence is greatest), low risk-allele frequency in Africans (where urate-related disease has historically been lower).

The Mechanism

rs6852441 lies within an intron of SLC2A9 and does not alter the GLUT9 protein sequence. Its functional significance, like other established intronic SLC2A9 variants (rs11942223, rs6815001, rs6814664), is regulatory: it tags a haplotype block that influences the expression, splicing, or basolateral trafficking of GLUT9 in renal proximal tubule cells. GLUT9 operates as a high-capacity electrogenic urate transporter, exchanging intracellular urate for extracellular glucose or fructose across the basolateral membrane. Variants on the risk haplotype appear to reduce net urate clearance, shifting the steady-state serum urate upward.

The C allele at rs6852441 (the GRCh38 reference) is the risk haplotype tag, found at approximately 90% frequency in East Asian populations — where gout incidence is among the highest globally — and at only about 38% in African populations, where urate-related disease has been lower. This inverse population gradient is consistent with the direction of effect seen for other established SLC2A9 intronic risk haplotype markers at this locus (Wei et al., 2014)²² (Wei et al., 2014).

The Evidence

SLC2A9 as the major urate locus: Two landmark 2008 Nature Genetics studies simultaneously established SLC2A9 as the most significant genetic determinant of serum uric acid in Europeans, with intronic variants explaining 1.7–5.3% of serum urate variance overall and up to 6% in women (Vitart et al., 2008)³³ (Vitart et al., 2008); (Döring et al., 2008)⁴⁴ (Döring et al., 2008). Carriers of risk alleles at SLC2A9 intronic variants show consistently higher serum uric acid across European, American Indian, Mexican American, and East Asian populations (Voruganti et al., 2013)⁵⁵ (Voruganti et al., 2013).

Complex local architecture: Detailed mapping of the 4p16.1 region by Wei et al. (2014) found that a five-SNP model incorporating marginal effects and epistatic interactions explained an additional 1.5% of serum urate variance beyond the lead SNP alone (Wei et al., 2014)⁶⁶ (Wei et al., 2014). The epistatically interacting SNPs are enriched at active enhancer chromatin marks in hepatic and blood cell lines, supporting a transcriptional regulation mechanism — consistent with rs6852441's intronic location at this locus.

Gout association: SLC2A9 intronic risk-allele carriers show elevated gout risk across multiple ethnic populations. Hollis-Moffatt et al. (2009) confirmed that major-allele genotypes at multiple SLC2A9 intronic variants were associated with gout in Māori, Pacific Island, and Caucasian case-control samples (OR >2.0 in Māori and Pacific groups) (Hollis-Moffatt et al., 2009)⁷⁷ (Hollis-Moffatt et al., 2009).

Sex-specific effects: The intronic SLC2A9 signal has a substantially larger effect in women than in men across all cohorts studied, with variance explained reaching ~6% in women versus ~1.2% in men. This sex difference is attributed to estrogen's independent stimulation of renal urate excretion, which amplifies the genetic signal in women but partially offsets it during the reproductive years (Döring et al., 2008)⁸⁸ (Döring et al., 2008).

Practical Actions

Carriers of CC at rs6852441 carry two copies of the risk haplotype tag associated with reduced renal urate clearance from this SLC2A9 signal. The practical implications follow the well-established SLC2A9 urate-management evidence base: eliminate sugar-sweetened beverages (the highest-leverage dietary action for SLC2A9 risk genotypes), reduce dietary purines, and establish a serum uric acid baseline to know where you stand.

The most important gene-environment interaction for this SLC2A9 locus is fructose: sugar-sweetened beverages raise urate through direct hepatic production and also impair GLUT9-mediated renal clearance through competitive inhibition, compounding the genetic risk from the C allele. Eliminating SSBs can reduce serum urate by 0.5–1 mg/dL in susceptible individuals — an effect comparable in magnitude to the genetic contribution of the risk haplotype itself.

Post-menopausal women with CC genotype are particularly exposed because estrogen's uricosuric contribution — which buffers the genetic risk during reproductive years — is withdrawn at menopause, often unmasking clinically significant hyperuricemia for the first time.

Interactions

rs11942223 (SLC2A9 intronic, independent signal): rs11942223 tags a second, genetically independent signal at the SLC2A9 locus (r² = 0.03–0.05 with rs3733591) with its own additive contribution to serum urate. Carrying risk alleles at both rs6852441 and rs11942223 compounds the urate elevation from two independent SLC2A9 regulatory mechanisms.

rs3733591 (SLC2A9 Arg265His missense): The coding variant Arg265His affects GLUT9 transport efficiency directly through a protein-level mechanism independent of rs6852441's regulatory effect. Risk alleles at both compounds the overall SLC2A9-mediated urate retention burden.

rs2231142 (ABCG2 Q141K): ABCG2 reduces intestinal urate secretion through an entirely separate pathway. Carrying risk alleles at rs6852441 (renal reabsorption) and ABCG2 rs2231142 (intestinal secretion) is additive and can produce serum urate above 7 mg/dL even without major dietary provocation.

Fructose and sugar-sweetened beverages: A gene-environment interaction between SLC2A9 genotype and SSB consumption has been documented at this locus: the normally urate-lowering protective allele has its benefit reversed by regular SSB intake, making fructose avoidance important regardless of which allele a person carries, and especially critical for CC risk-allele homozygotes.

Aromatase¹¹ Aromatase
the enzyme encoded by CYP19A1 that catalyzes the conversion of androgens to estrogens, the final step in estrogen biosynthesis is expressed in the ovaries, adipose tissue, breast, bone, and brain. Local aromatase activity determines the estrogen microenvironment in hormone-sensitive tissues, and variants that alter CYP19A1 transcription or regulatory activity can shift the androgen-to-estrogen balance in ways relevant to cancer biology, reproductive function, and bone health. rs7167936 sits at chromosome 15 position 51,207,348 (GRCh38) — approximately 709 bp upstream of the annotated CYP19A1 transcription start site and within an intron of the neighboring non-coding RNA gene MIR4713HG. It maps to the CYP19A1 RefSeqGene (NG_007982.1:g.136251T>C), placing it squarely in the regulatory zone that governs aromatase expression in peripheral tissues.

The Mechanism

rs7167936 is classified as an intron variant in the MIR4713HG host gene transcript but lies within the broader CYP19A1 genomic locus. The CYP19A1 gene is on the minus strand of chromosome 15, meaning that the plus-strand coordinate 51,207,348 is upstream of the 3' (coding) end of the gene and near the region containing tissue-specific promoter elements. CYP19A1 is unusual in that it uses at least ten different tissue-specific promoters spread over ~93 kb of upstream sequence, with different promoter elements driving expression in the ovary, adipose tissue, bone, and brain. Variants in this regulatory region can alter which tissues express aromatase, at what level, and in response to which hormonal signals — without changing the protein itself.

rs7167936 has not been directly characterized for transcription factor binding or allele-specific expression, unlike the better-studied rs1062033 (CEBPβ binding) or rs700518 (splicing-related). Its functional significance is inferred from population-level association signals rather than from direct mechanistic studies.

The Evidence

The primary evidence for rs7167936 comes from Darabi et al. 2011²² Darabi et al. 2011
Breast Cancer Research and Treatment — 1,569 Swedish breast cancer patients; rs7167936 associated with histological grade (p=0.010) and tumor size (p=0.005; 1-sided). The study examined genetic variation across the androgen-to-estrogen conversion pathway in relation to tumor characteristics. rs7167936 associations with grade and size persisted when restricted to ER-positive tumors (p=0.008 and p=0.011), consistent with an estrogen-pathway mechanism influencing tumor biology rather than an off-target effect. rs4646 showed the strongest single-SNP associations in the same study, with the common CYP19A1 allele linked to low histological grade and smaller tumor size.

The variant has not been independently replicated for the specific associations with histological grade and tumor size. The evidence base is therefore limited to a single cohort and qualifies as emerging rather than strong. No ClinVar submissions exist, and no pharmacogenomics guidelines reference this variant. The broader CYP19A1 locus harbors multiple variants with stronger and better-replicated associations — rs727479, rs4646, rs10046, rs700518, and rs1062033 — with which rs7167936 may be in partial linkage disequilibrium, though formal LD data are not readily available.

Glubb et al. 2017³³ Glubb et al. 2017
review of CYP19A1 variation and aromatase inhibitor outcomes concluded that rs727479 best captures the CYP19A1 signal for circulating estradiol and that rs4646 (in LD with rs727479) was the only variant replicating across studies for aromatase inhibitor treatment outcomes. The position of rs7167936 near the CYP19A1 regulatory zone suggests it may tag this same haplotype block, though this requires formal confirmation.

Practical Actions

For carriers of the G allele (one or two copies), the evidence base is currently too limited to support specific clinical recommendations independent of the variant's broader CYP19A1 haplotype context. The primary actionable implication is awareness for women with a personal or family history of hormone receptor-positive breast cancer: the Darabi cohort data suggest this locus tags a biological signal influencing breast cancer tumor behavior, though the association is from a single study and the allele-specific direction requires clarification from the full text of the original paper.

Women undergoing surveillance for hormone-sensitive cancers or those with known CYP19A1 haplotype risk should discuss this variant alongside the better-characterized SNPs at the same locus (rs4646, rs10046, rs700518) with their clinician, as haplotype context may provide more interpretive power than any single variant in isolation.

Interactions

rs7167936 resides within the broader CYP19A1 regulatory zone that contains rs700518 (~12 kb upstream), rs1062033 (~12 kb upstream), rs10046 (in the 3'UTR), and rs4646 (in intron 4). These variants form multiple haplotype blocks and their combined effect on aromatase expression has been studied in bone, breast, and endometrium. The association of rs7167936 with breast tumor characteristics in the Darabi cohort was studied in the context of all these variants simultaneously; it is plausible that rs7167936 tags a haplotype shared with one or more of these better-characterized variants, though formal LD mapping at this position is needed.

Every cell in your body needs cholesterol to build membranes and synthesize hormones. To keep blood LDL from accumulating, the LDLR gene¹¹ LDLR gene
Low-density lipoprotein receptor: a cell-surface protein that captures LDL particles circulating in blood and pulls them into cells for degradation, removing them from the bloodstream encodes a receptor that acts like a molecular claw — binding LDL particles at the cell surface, pulling them inside, releasing the LDL into the lysosome for processing, and then recycling back to the surface to repeat the cycle. rs730882094 introduces a single amino acid change at position 316 of this receptor protein — swapping asparagine for serine — within one of the receptor's critical EGF-like repeat domains²² EGF-like repeat domains
EGF precursor homology domain: a structural region of the LDLR that enables acid-dependent release of LDL in the endosome and receptor recycling back to the cell surface. Mutations here often impair LDLR biosynthesis, trafficking to the cell surface, or the conformational switch needed for pH-dependent LDL release. The consequence is impaired receptor processing, reduced LDL clearance, and lifelong elevation of LDL cholesterol — the hallmark of familial hypercholesterolemia (FH).

FH is one of the most common inherited metabolic disorders³³ one of the most common inherited metabolic disorders
Familial hypercholesterolemia affects an estimated 1 in 200–250 individuals globally (heterozygous form), yet fewer than 10% are diagnosed or treated in most countries, but LDLR variant–specific entries like Asn316Ser are rare — gnomAD records only 11 G-allele chromosomes among 1.4 million in the exome database (~0.001%). The variant was classified as Likely Pathogenic⁴⁴ classified as Likely Pathogenic
ClinVar VCV000183103: 4 of 6 expert submissions classify this as Likely Pathogenic for familial hypercholesterolemia; 2 classify as Uncertain Significance. The LP classifications come from the British Heart Foundation LDLR-LOVD database, Color Diagnostics, All of Us Research Program (NIH), and Charité Berlin for familial hypercholesterolemia by multiple independent submitters.

The Mechanism

The LDLR protein consists of several domains: an LDL-binding domain at the N-terminus, followed by EGF precursor homology (EGFPH) repeats A, B, and C that control pH-dependent LDL release and receptor recycling. Asn316 sits within EGF-like repeat A (amino acids 315–354), a region enriched for pathogenic LDLR variants⁵⁵ enriched for pathogenic LDLR variants
Functional studies from ClinVar submitter Merck Research Labs show this variant "interferes with protein transport and significantly affects LDLR biosynthesis or turnover," consistent with the known functional role of EGF-A domain asparagines in receptor folding and glycosylation and one where asparagine residues are known to be important for N-linked glycosylation, protein folding, and intracellular trafficking. Substituting serine at position 316 disrupts these interactions, impairing the receptor's maturation and transport to the cell surface.

The result is a reduced number of functional LDL receptors available to clear circulating LDL particles. LDL accumulates in plasma, depositing in arterial walls over decades and driving accelerated atherosclerosis. In untreated FH heterozygotes (carrying one mutant LDLR allele), LDL-C typically runs 2–4× above population norms from birth — a cumulative atherogenic burden that manifests as premature coronary artery disease, often before the fifth decade of life.

The Evidence

The classification of this variant rests on a combination of evidence:

Functional data: Merck Research Labs functional profiling data in ClinVar documents that Asn316Ser "interferes with protein transport and significantly affects LDLR biosynthesis or turnover" — a non-trivial mechanistic finding even if the full study data are unpublished. Computational predictions are conflicting (SIFT: deleterious; PolyPhen-2: benign), which is common for variants in the EGF domain where the structural context matters more than biochemical similarity scores.

Clinical observations: Five heterozygous carriers in one series⁶⁶ Five heterozygous carriers in one series
ClinVar submitter Molecular Genetics Lab, Centre for Cardiovascular Surgery, Czech Republic — observed 5 individuals aged 22–53 with clinical FH features: hypercholesterolemia, xanthelasma, tendon xanthomas, and corneal arcus (for the closely related Asn316Thr variant at the same codon) presented with classic FH clinical features, strengthening the pathogenic case for this codon.

Disease context: Defesche et al.'s landmark 2017 review⁷⁷ Defesche et al.'s landmark 2017 review
Defesche JC et al. Familial hypercholesterolaemia. Nat Rev Dis Primers, 2017 established that untreated FH confers up to a 13-fold increased risk of coronary heart disease compared to the general population, with event risk accumulating silently from childhood. Nordestgaard et al.'s European Atherosclerosis Society consensus⁸⁸ Nordestgaard et al.'s European Atherosclerosis Society consensus
Nordestgaard BG et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population. Eur Heart J, 2013 set adult LDL-C targets below 2.5 mmol/L (≈97 mg/dL) for FH patients and below 1.8 mmol/L (≈70 mg/dL) for those with established coronary disease.

The aggregate classification of Likely Pathogenic (rather than Pathogenic) reflects the relatively small number of independent affected families described to date for this specific allele, and conflicting computational predictions. As data accumulate, reclassification to Pathogenic is possible.

Practical Actions

For heterozygous carriers of rs730882094 G, the key priorities are: (1) confirm LDL-C elevation with a fasting lipid panel, (2) initiate high-intensity statin therapy as early as feasible, (3) cascade-test first-degree relatives, and (4) manage all co-occurring cardiovascular risk factors aggressively.

Statins remain the first-line treatment⁹⁹ Statins remain the first-line treatment
High-intensity statins (rosuvastatin 20–40 mg, atorvastatin 40–80 mg) reduce LDL-C by 50–55% as monotherapy. Addition of ezetimibe provides a further 15–20% reduction. PCSK9 inhibitors (evolocumab, alirocumab) achieve an additional 50–60% reduction and are indicated when LDL-C target is not achieved with maximum tolerated statin + ezetimibe for FH. Early treatment reduces lifetime atherosclerotic burden. In FH heterozygotes without other risk factors, treatment targets LDL-C below 2.5 mmol/L (97 mg/dL); in those with existing cardiovascular disease, below 1.8 mmol/L (70 mg/dL).

Interactions

LDLR Asn316Ser interacts with other genetic modifiers of LDL metabolism. APOE genotype (rs429358 / rs7412) modulates LDL levels independently — carriers of APOE ε4 alongside an LDLR variant may have even higher LDL than expected from the LDLR mutation alone. PCSK9 gain-of-function variants (e.g., rs28942453 / PCSK9 D374Y) accelerate LDLR degradation and compound the receptor deficit; PCSK9 loss-of-function variants are protective and may blunt FH severity. APOB variants (e.g., rs121908028 / APOB R3527Q) cause a clinically identical FH phenotype through a different mechanism (impaired LDL particle binding rather than receptor dysfunction). Genetic testing panels for FH routinely screen all three genes simultaneously.

When the hepatitis B virus enters the body, the immune system must decide within weeks whether to mount a clearing response or allow the infection to persist for life. That decision hinges heavily on HLA class II antigen presentation¹¹ HLA class II antigen presentation
The process by which antigen-presenting cells — dendritic cells, macrophages, B cells — display viral peptide fragments on MHC class II molecules to CD4+ T helper cells, initiating adaptive immunity. rs7770370 sits within the HLA-DPB1 gene on chromosome 6p21 and marks a haplotype block that controls how efficiently the immune system presents HBV antigens. The G allele at this position tags a low-expression HLA-DP haplotype — carriers produce fewer HLA-DP antigen-presenting complexes, mount weaker T-cell responses to HBV, and face significantly higher odds of chronic infection and vaccine non-response.

The Mechanism

HLA-DP is a heterodimeric surface receptor composed of an alpha chain (HLA-DPA1) and a beta chain (HLA-DPB1), expressed on antigen-presenting cells including the Kupffer cells and dendritic cells of the liver. It binds viral peptide fragments in its groove and displays them to CD4+ T helper cells²² CD4+ T helper cells
The immune cells that coordinate both antibody production by B cells and activation of CD8+ cytotoxic T cells — the two arms of adaptive immunity needed to clear HBV. rs7770370 is an intronic variant in HLA-DPB1 that does not change the protein sequence — instead, it acts as a tag SNP³³ tag SNP
A marker in strong linkage disequilibrium with the functional haplotype; it doesn't cause the effect itself but reliably identifies carriers of the causally relevant low-expression haplotype for a haplotype including the eQTL variants rs3077 (HLA-DPA1 3′ UTR) and rs9277535 (HLA-DPB1 3′ UTR), both of which directly reduce HLA-DP mRNA expression. The G allele at rs7770370 co-segregates with the G allele at rs3077 and the A allele at rs9277535 — the combination associated with the lowest HLA-DPA1 and HLA-DPB1 surface density on liver antigen-presenting cells. With fewer HLA-DP molecules available, HBV peptide display to CD4+ T cells is impaired, T-helper activation is blunted, antibody production against the HBV surface antigen (anti-HBs) is reduced, and cytotoxic T-cell killing of infected hepatocytes is diminished.

The Evidence

Wu et al. (2015)⁴⁴ Wu et al. (2015)
SNP rs7770370 in HLA-DPB1 loci as a major genetic determinant of response to booster hepatitis B vaccination. J Gastroenterol Hepatol performed the first GWAS specifically focused on rs7770370, studying 15- to 18-year-olds who had received primary HBV vaccination in infancy but failed to maintain protective antibody levels. Among HLA-DP candidate SNPs in a 47 kb block, rs7770370 was the sentinel signal: AA homozygotes had an adjusted odds ratio of just 0.095 (CI 0.030–0.307) for vaccine non-response relative to GG homozygotes — a greater than 10-fold difference — while AG heterozygotes showed a 2-fold advantage (OR 0.524). This quantified the G allele as the dominant genetic driver of long-term vaccine failure in this population.

Roh et al. (2016)⁵⁵ Roh et al. (2016)
HLA-DP variants and hepatitis B vaccine responsiveness in Korean infants. Vaccine extended the finding to 290 infants (the primary vaccination setting), showing that the AA genotype was associated with vaccine response (relative risk 2.5, p=0.033) and with high-titer response specifically (RR 2.7, p<0.001). The A allele was significantly more frequent in responders (p<0.01), confirming the genotype predicts immunogenicity from the very first vaccination series.

For chronic HBV infection susceptibility, Huang et al. (2020)⁶⁶ Huang et al. (2020)
Taiwan Biobank GWAS of 15,352 HBV-exposed participants. Aliment Pharmacol Ther identified rs7770370 as the single most significant HLA class II signal for HBV chronicity (P=2.73×10⁻³⁵, Pcorrected <8.6×10⁻⁸). The HLA-DPB1*05:01 allele — in strong LD with the G allele — conferred OR 1.61 (CI 1.29–2.01) for chronic HBV. In a Thai GWAS, Ashouri et al. (2022)⁷⁷ Ashouri et al. (2022)
Genome-wide Association Study for Chronic Hepatitis B in the Thai Population. Front Genet independently replicated the association (p=7.71×10⁻¹⁰, OR=0.49 for the protective A allele). The association is present across Asian, European, and mixed-ancestry cohorts, though the G allele is far more common in populations with historically high HBV endemicity — about 46–54% in East Asians and Africans versus only 13% in Europeans — a pattern consistent with ongoing selection pressure from the virus.

Practical Actions

The key clinical implication is twofold: vaccine response and infection susceptibility. G-allele carriers — especially GG homozygotes — are at substantially higher risk of failing to develop protective antibodies after standard HBV vaccination, and of progressing to chronic infection if exposed. The appropriate actions are checking post-vaccination antibody titres and, for those with exposure risk, baseline serology and follow-up for signs of chronicity.

For those already identified with chronic HBV infection, the HLA-DP haplotype also predicts treatment response dynamics — AA haplotype carriers have better HBsAg seroclearance during nucleot(s)ide analogue therapy, making genotype relevant to hepatologist treatment planning.

Interactions

rs7770370 is part of the same HLA-DP haplotype block as rs3077 (HLA-DPA1 3′ UTR) and rs9277535 (HLA-DPB1 3′ UTR). These three variants tag a low-expression haplotype that produces reduced HLA-DPA1 and HLA-DPB1 mRNA. The combined protective haplotype (A allele at rs3077 and A allele at rs9277535) shows a stronger additive protective effect against chronic HBV (OR 0.57 in Indonesian replication, CI 0.36–0.92) than either variant alone. Profiling all three SNPs together provides the most complete picture of HLA-DP expression and HBV susceptibility in a given individual. Each additional G allele across this haplotype incrementally reduces HLA-DP surface density and immune clearance capacity.